Pediatric Immunization

Here, the 5 key signs and symptoms that characterize measles in the order of appearance.

Your daily dose of the clinical news you may have missed.

Findings support current CDC recommendations that all infants should be protected by maternal RSV vaccination or infant receipt of nirsevimab.

Just when the new monovalent COVID-19 vaccines were available in Sept 2023, a new variant emerged. Did the CDC get it right? What do you know about the monovalent VE?

According to a new CDC report, 38.6% of children aged 9-17 years received ≥1 doses of the HPV vaccine in 2022.

Should you pregnant patient get the new RSV vaccine at the appropriate time during gestation or wait and have the baby receive Beyfortus after birth?

Measles cases are reported in 6 states, which is not a surprise to one pediatrician who points to the ongoing consequences of falling vaccination rates.

Your daily dose of the clinical news you may have missed.

Vaccination against SARS-CoV-2 was associated with reduced risk of long COVID for at least 12 months in children and adolescents in a new large retrospective study.

Click through a short slideshow review of the available COVID-19 vaccines for adults and children and of the long COVID symptoms to watch for in all your patients.

Tell us what features you would find most valuable in a rapid point-of-care test for simultaneous detection of respiratory viruses in pediatric patients.

The best defense against long COVID remains COVID-19 vaccination. This short slide show highlights long COVID symptoms and CDC vaccination recommendations.

Experts discuss the efficacy of the latest vaccines against currently circulating strains of COVID-19, commenting on how long immunity lasts from these vaccines.

Drs Tina Q Tan and Rodney Rohde review the importance of vaccinating against COVID-19 to prevent long COVID, as well as highlight the current vaccination recommendations.

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

Misinformation about COVID-19 vaccines may have eroded parents' trust in vaccination for their children, according to authors of new research.

Nonmedical exemptions from required school vaccinations accounted for more than 90% of the increase, according to the published data.

The world's first maternal vaccine against RSV in neonates and infants was approved in August. This brief slide show highlights the clinical trials that made history.

Collaboration among care team members is a key ingredient to effective support for children with disabilities and this specialist says her welcome mat is out for her neighbors.

The Pfizer product is the first vaccine indicated to prevent the 5 most common serogroups causing meningococcal disease in adolescents and young adults.

IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.

The monovalent, singe-shot COVID-19 vaccine simplifies what used to be a complicated conversation with patients and stocking the vaccine fridge, too, says Steven Furr, MD.

Experts conclude their discussion on the efficacy and safety study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on possible dosing strategies and key takeaways from this study.

Experts discuss the results of the safety and efficacy study of nirsevimab for Respiratory Syncytial Virus (RSV) commenting on the adverse events observed in the test and placebo groups.

Experts discuss how infant weight related to efficacy outcomes of nirsevimab for Respiratory Syncytial Virus (RSV), providing their clinical expertise on why this may have occurred and what improvements can be made to mitigate these differences.

Experts discuss data relating to the strains of Respiratory Syncytial Virus (RSV) and how clinicians should consider them in relation to the efficacy of nirsevimab.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, continue their discussion on the results of nirsevimab for Respiratory Syncytial Virus (RSV) and offer insights on how this may change therapeutic approaches in the future.

Tina Tan, MD, FAAP, FIDSA, FPIDS, and Flor M. Munoz, MD, MSc, discuss the initial efficacy data of the study on nirsevimab for Respiratory Syncytial Virus (RSV) and how it compared to placebo.

Flor M. Munoz, MD, MSc, and Tina Tan, MD, FAAP, FIDSA, FPIDS, discuss the patient population of the safety and efficacy study on nirsevimab for Respiratory Syncytial Virus (RSV).